ARCT
Price
$16.90
Change
-$0.11 (-0.65%)
Updated
Sep 2, 04:08 PM (EDT)
Capitalization
461.9M
64 days until earnings call
CABA
Price
$1.45
Change
-$0.00 (-0.00%)
Updated
Sep 2, 04:13 PM (EDT)
Capitalization
132.62M
71 days until earnings call
Interact to see
Advertisement

ARCT vs CABA

Header iconARCT vs CABA Comparison
Open Charts ARCT vs CABABanner chart's image
Arcturus Therapeutics Holdings
Price$16.90
Change-$0.11 (-0.65%)
Volume$225
Capitalization461.9M
Cabaletta Bio
Price$1.45
Change-$0.00 (-0.00%)
Volume$1.5K
Capitalization132.62M
ARCT vs CABA Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
ARCT vs. CABA commentary
Sep 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a StrongBuy and CABA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 02, 2025
Stock price -- (ARCT: $17.01 vs. CABA: $1.45)
Brand notoriety: ARCT and CABA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 91% vs. CABA: 83%
Market capitalization -- ARCT: $461.9M vs. CABA: $132.62M
ARCT [@Biotechnology] is valued at $461.9M. CABA’s [@Biotechnology] market capitalization is $132.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.25B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileCABA’s FA Score has 1 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • CABA’s FA Score: 1 green, 4 red.
According to our system of comparison, ARCT is a better buy in the long-term than CABA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 5 TA indicator(s) are bullish while CABA’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 5 bullish, 5 bearish.
  • CABA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than CABA.

Price Growth

ARCT (@Biotechnology) experienced а -8.10% price change this week, while CABA (@Biotechnology) price change was -10.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.63%. For the same industry, the average monthly price growth was +22.15%, and the average quarterly price growth was +32.77%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2025.

CABA is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+6.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($462M) has a higher market cap than CABA($133M). ARCT YTD gains are higher at: 0.236 vs. CABA (-36.123). ARCT has higher annual earnings (EBITDA): -54.54M vs. CABA (-140.83M). ARCT (196M) and CABA (195M) have equal amount of cash in the bank . CABA has less debt than ARCT: CABA (24.9M) vs ARCT (27M). ARCT has higher revenues than CABA: ARCT (110M) vs CABA (0).
ARCTCABAARCT / CABA
Capitalization462M133M347%
EBITDA-54.54M-140.83M39%
Gain YTD0.236-36.123-1%
P/E RatioN/AN/A-
Revenue110M0-
Total Cash196M195M101%
Total Debt27M24.9M108%
FUNDAMENTALS RATINGS
ARCT vs CABA: Fundamental Ratings
ARCT
CABA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
44
Fair valued
12
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4288
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CABA's Valuation (12) in the null industry is in the same range as ARCT (44) in the Pharmaceuticals Major industry. This means that CABA’s stock grew similarly to ARCT’s over the last 12 months.

CABA's Profit vs Risk Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that CABA’s stock grew similarly to ARCT’s over the last 12 months.

ARCT's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as CABA (98) in the null industry. This means that ARCT’s stock grew similarly to CABA’s over the last 12 months.

ARCT's Price Growth Rating (42) in the Pharmaceuticals Major industry is somewhat better than the same rating for CABA (88) in the null industry. This means that ARCT’s stock grew somewhat faster than CABA’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as CABA (100) in the null industry. This means that ARCT’s stock grew similarly to CABA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTCABA
RSI
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 5 days ago
83%
Bullish Trend 5 days ago
73%
Momentum
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 5 days ago
90%
MACD
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 5 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 5 days ago
87%
Bearish Trend 5 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 5 days ago
80%
Bearish Trend 5 days ago
88%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 12 days ago
87%
Declines
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 5 days ago
90%
Bullish Trend 5 days ago
69%
Aroon
ODDS (%)
Bullish Trend 5 days ago
84%
Bearish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CABA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MRINQ0.710.06
+9.23%
Marin Software Inc.
SNOTF0.51N/A
N/A
Sinotrans Ltd.
SGBG16.50N/A
N/A
Signature Bank Georgia Sandy Springs
NPNVF23.00N/A
N/A
Valqua Ltd.
CCHGY50.54-0.09
-0.18%
Coca-Cola HBC AG

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with RGNX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then RGNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-1.68%
RGNX - ARCT
51%
Loosely correlated
-0.89%
CLDX - ARCT
49%
Loosely correlated
-1.34%
RXRX - ARCT
46%
Loosely correlated
-3.39%
MRNA - ARCT
46%
Loosely correlated
-1.55%
MGNX - ARCT
46%
Loosely correlated
+4.12%
More

CABA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CABA has been loosely correlated with IPSC. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CABA jumps, then IPSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CABA
1D Price
Change %
CABA100%
-3.33%
IPSC - CABA
51%
Loosely correlated
-1.68%
GBIO - CABA
46%
Loosely correlated
-2.76%
ARWR - CABA
46%
Loosely correlated
-1.39%
KYTX - CABA
45%
Loosely correlated
+0.27%
ARCT - CABA
45%
Loosely correlated
-1.68%
More